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Abstract
Background: MicroRNAs (miRNA) are ~19–25 nucleotide long RNA molecules that fine tune gene expression
through the inhibition of translation or degradation of the mRNA through incorporation into the RNA induced
silencing complex (RISC). MicroRNAs are stable in the serum and plasma, are detectable in a wide variety of body
fluids, are conserved across veterinary species and humans and are expressed in a tissue specific manner. They can
be detected at low concentrations in circulation in animals and humans, generating interest in the utilization of
miRNAs as serum and/or plasma based biomarkers of tissue injury. MicroRNA tissue profiling in rodents has been
published, but sample an insufficient number of organs of toxicologic interest using microarray or qPCR technologies
for miRNA detection. Here we impart an improved rat microRNA body atlas consisting of 21 and 23 tissues of
toxicologic interest from male and female Sprague Dawley rats respectively, using Illumina miRNA sequencing.
Several of the authors created a dog miRNA body atlas and we collaborated to test miRNAs conserved in rat and
dog pancreas in caerulein toxicity studies utilizing both species.
Results: A rich data set is presented that more robustly defines the tissue specificity and enrichment profiles of
previously published and undiscovered rat miRNAs. We generated 1,927 sequences that mapped to mature
miRNAs in rat, mouse and human from miRBase and discovered an additional 1,162 rat miRNAs as compared to
the current number of rat miRNAs in miRBase version 21. Tissue specific and enriched miRNAs were identified
and a subset of these miRNAs were validated by qPCR for tissue specificity or enrichment. As an example of the
power of this approach, we have conducted rat and dog pancreas toxicity studies and examined the levels of
some tissue specific and enriched miRNAs conserved between rat and dog in the serum of each species. The
studies demonstrate that conserved tissue specific/enriched miRs-216a-5p, 375-3p, 148a-3p, 216b-5p and 141-3p
are candidate biomarkers of pancreatic injury in the rat and dog.
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Conclusions: A microRNA body atlas for rat and dog was useful in identifying new candidate miRNA biomarkers
of organ toxicity in 2 toxicologically relevant species.
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Background
The drug discovery process is a long and expensive en-
deavor with many experimental molecules failing in late
stage in vivo toxicology studies. The high attrition rate
of drugs in late stage clinical trials lead to the call for in-
vestigation of the utilization of species translatable bio-
markers to select safer compounds early in the drug
development process [1]. In order to better understand
toxicities in preclinical and clinical settings and to speed
the development of new therapies, body fluid based bio-
markers of organ damage have been sought to both
identify and monitor toxicities. Serum or plasma based
biomarkers capable of monitoring tissues affected by
drug toxicity could allow for the detection of tissue in-
jury from simple blood draws, thus permitting larger
numbers of compounds to be tested more rapidly in
studies that are less expensive and use fewer animals
compared to traditional means of toxicity evaluation.
The properties of an ideal biomarker include tissue spe-
cificity, a strong correlation to organ dysfunction or tox-
icity, a strong association to histopathologic changes,
robust sensitivity, predictability, accessibility through a
noninvasive method, readily-available rapid and inexpen-
sive assays for quantitative measurement and direct
translatability across preclinical species and human.
Serum based biomarkers of organ dysfunction have
been useful in preclinical and clinical settings. Serum
AST (aspartate aminotransferase) and ALT (alanine ami-
notransferase) were discovered in 1957 [2] and have
been used in combination with total bilirubin, gamma-
glutamyl transferase (GGT), alkaline phosphatase (ALP),
albumin and bile acids as markers of liver injury to de-
risk compounds in preclinical drug development [3, 4]
as well as being utilized for monitoring liver toxicity in
clinical drug development [5]. Additional markers of
hepatotoxicity are currently under investigation [6]. Car-
diac troponin I is a sensitive and specific serum based
biomarker of cardiac injury in humans and mice and has
been employed to mitigate cardiac toxicity in mouse
toxicology studies with novel kinase inhibitors [7]. Urine
based biomarkers for evaluation of renal toxicity include
BUN (blood urea nitrogen), creatinine, urinary albumin,
KIM-1 (kidney injury molecule-1), NGAL (neutrophil
gelatinase associated lipocalin) and cystatin C [8]. Amylase
and lipase have been used as markers for pancreatitis, but
their diagnostic capability is limited by sensitivity and spe-
cificity [9]. These preclinical and clinical biomarkers are
carefully reviewed in Dieterle, 2009 [8]. Despite the suc-
cess with protein based biomarkers to date, gaps in our
ability to detect toxicities in a number of organs prevent
the widespread utilization of biomarkers in toxicology
studies. Current gaps in the minimally-invasive biomarker
portfolio include gastrointestinal injury, CNS (central ner-
vous system) injury, reproductive toxicity and specific
markers of glomerular and liver injury. Clinical chemistry
parameters offer important information regarding the
health of a given organ but can be limited by lack of speci-
ficity and sensitivity as in the cases of ALT and AST for
liver injury and amylase and lipase for injury in the exo-
crine pancreas [8]. While protein based biomarkers pro-
vide useful information, they can be limited in their
translation across species and to the clinical setting due to
species differences in the biomarkers and the need for spe-
cies specific immunoassay reagents.
Traditional pre-clinical methods for assessing the po-
tential toxicity of a compound include clinical chemistry,
histopathology, hematology, physiological measurements
and clinical observations, but the concordance rate to
human toxicity was reported by Olsen et al. to be 71 %
leaving room for significant improvement in preclinical
toxicology studies [10]. Unfortunately, the concordance
of clinical chemistry or other biomarkers was not dir-
ectly compared to establish concordance between pre-
clinical and clinical studies; Several groups advised more
use of biomarkers in preclinical and clinical studies [10].
In a subsequent study, adverse drug reactions in each
target organ from compounds approved in Japan from
2001–2010 were found to be 48 % concordant between
preclinical toxicology studies and humans while changes
in laboratory parameters displayed a 30-70 % correlation
[11]. It is evident that additional endpoints indicative of
organ toxicities that are translatable and/or predictive
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from preclinical species to human are necessary to im-
prove the safety of compounds in preclinical drug devel-
opment and clinical trials. With the end goal of identifying
tissue specific, species translatable blood based biomarkers
of tissue injury, we set out to characterize the rat micro-
RNA expression profile in various organs and create a rat
microRNA body atlas to identify specific and enriched
miRNAs in individual tissues.
MicroRNAs are 21–25 nucleotide long RNA mole-
cules whose cellular function appears to be to inhibit
translation or cause degradation of their mRNA target
or targets [12]. Some miRNAs are expressed in high
abundance in a tissue specific manner, are resistant to
degradation in the serum, are well conserved in preclin-
ical species including mouse, rat, macaque and human,
and are detectable in a wide variety of biologic fluids
[13–21]. In addition, sensitive, specific and readily
available qPCR based assays exist to measure miRNAs
making them attractive candidates for serum based bio-
markers for organ injury. Perhaps the most well charac-
terized miRNA for use as a toxicity biomarker is the
liver enriched miR-122-5p. This miRNA was increased
in the serum of rats that were given the liver toxicant
trichlorobromomethane, but not increased in the serum
of rats administered the skeletal muscle toxicants 2,3,5,6
tetramethyl-p-phenylenediamine (TMPD) and an HMG-
CoA reductase inhibitor [22]. AST and ALT were in-
creased when animals were given liver or skeletal muscle
toxicants, demonstrating that miR-122 was indicative of
liver injury only and not muscle injury, thus displaying
an advantage in specificity over ALT and AST. Mice
treated with acetaminophen displayed increases of miR-
122 in the serum 2 h before an increase of AST/ALT
[23]. Additionally, miR-122 and liver enriched miR-192
were increased in the serum of patients who had acet-
aminophen induced hepatotoxicity demonstrating the
potential for these miRNAs to be used as both preclin-
ical and clinical biomarkers for liver injury [24]. In a fur-
ther study miR-122, HMGB1, Cytokeratin 18 and GLDH
were able to predict patients who would develop liver
failure as a result of acetaminophen overdose even when
ALT remained in the normal range [25].
While several miRNA tissue profiling experiments
have been reported in mouse, rat and human, these ro-
dent experiments do not encompass the range of tissues
relevant to toxicology studies for drug candidates. In
addition, published studies relied upon microarray and/
or qPCR based technologies which could suffer from a
lack of specificity and sensitivity. Microarrays also do
not allow for the identification of novel miRNAs due to
their dependence on known sequences and may not ac-
count for tissue expression of isomiRs, which are miR-
NAs that have variations from the reference miRNA
sequence [26]. QPCR also lacks specificity in cases
where 2 miRNAs have a closely aligned sequence. As an
example, miR-1 expressed in skeletal muscle and heart
and miR-206 expressed specifically in skeletal muscle
differ by only 3 bases. Several of the current qPCR based
assays for miR-1 also detect synthetic miR-206 (Author
observations) indicating that caution must be taken
when using this approach.
Next generation sequencing (NGS) is a preferred
method for miRNA profiling because it makes direct, un-
biased and quantitative measures of known and unknown
miRNAs. In order to realize the true potential of miRNAs
as biomarkers of organ damage it is critical to comprehen-
sively understand the tissue expression pattern of miRs
and isomiRs, and this can be best achieved using NGS.
Therefore we have constructed a rat miRNA body
atlas using Illumina miRNA sequencing from 5 male
and 5 female Sprague Dawley rats and 21 and 23 or-
gans of toxicologic interest from each sex, respectively
1. In parallel to this effort, several of the authors have
constructed a similar canine body atlas from 16 tis-
sues from 5 male Marshall beagle dogs. Publication of
both miRNA body atlases will provide an invaluable
resource for the characterization of potential bio-
markers of organ injury in 2 most commonly used
species for preclinical safety assessment.
Here we present the findings of the rat miRNA body
atlas in which we have identified 1,162 previously unre-
ported miRNAs in the rat and detailed numerous tissue
specific and enriched miRNAs. We have discovered sev-
eral novel tissue specific miRNAs in each species, some
of which are conserved across both rat and dog, and
some which are species specific 1. Comparison of the rat
and dog atlases yielded candidate liver and pancreas spe-
cific biomarkers. The potential pancreas biomarkers
were tested in rat and dog toxicology studies using the
pancreatic toxicant caerulein, while the potential liver
biomarkers were tested in toxicology studies conducted
by Takeda. In these proof-of-concept studies, miRNAs
performed as well as or better than traditional markers
of pancreatic injury, demonstrated a much larger dy-




Five male and five female Sprague Dawley rats 12–13
weeks in age were obtained from Charles Rivers Labora-
tories and euthanized by CO2 asphyxiation. The rats
were necropsied and tissues were placed into RNAlater®
within 5 min of asphyxiation. Organs (liver, kidney, kid-
ney medulla, kidney cortex, heart, pancreas, adrenal,
glandular stomach, non-glandular stomach, duodenum,
jejunum, ileum, cerebrum, cerebellum, hippocampus,
brainstem, dorsal root ganglion, soleus, biceps femoris,
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testis, ovaries, uterus and whole blood) were processed
in batches according to approximate tissue size as fol-
lows and placed into RNAlater® at 4 °C for 24 h and
were transferred to-20C the following day. In batch #1,
greater than 150 mg of liver, stomach, ileum, jejunum
and duodenum were placed into RNAlater® for subse-
quent total RNA isolation. The following portions of the
intestine corresponding to the segment that is routinely
collected for histology were collected: the stomach with
approximately 5 cm of the duodenum attached, a 10 cm
section from the midpoint of the jejunum and the distal
5 cm of ileum. A syringe containing RNAlater® was used
to flush the contents from the lumen of the collected
segments prior to placing them into the RNAlater® col-
lection tube. In batch #2, ~150 mg of kidney, pancreas,
brain, testis, biceps and soleus were placed into RNAla-
ter® for subsequent total RNA isolation. In batch #3, 30-
50 mg of adrenal, heart, ovary and uterus were placed
into RNAlater® for subsequent total RNA isolation.
RNA Extraction
Tissues were removed from RNAlater®, frozen in liquid
nitrogen and pulverized according to the Covaris tissue
pulverization protocol [27]. Tissues were placed in an
appropriate volume of Qiazol and homogenized using
lysing D matrix tubes (MP Biomedicals, Cat# 6913–100).
Qiazol volume was scaled up according to the mass of
tissue to be homogenized. Total RNA was next isolated
and eluted into 80ul of 95 °C molecular biology grade
water. RNA quality was assessed using the Agilent 2100
Bioanalyzer using the RNA pico kit. All RNAs except for
pancreas, 3/10 hippocampus samples and 1 uterus sam-
ple had RIN (RNA Integrity Number) values of 7 or
higher with an average RIN value of 7.88. For samples
that displayed RIN values lower than 7 the RNA extrac-
tion protocol was repeated using additional Qiazol/Tis-
sue homogenate. Most samples achieved RIN values
greater than 7 as shown in Fig. 1. Whole blood was
placed into RNAlater® for blood and all RNAs were
Fig. 1 The tissues used for construction of the rat miRNA body atlas and boxplots of the RIN values associated with the tissues from 5 male and
5 female Sprague Dawley rats are illustrated above. RNAs were extracted from rat tissues and were tested for RNA quality using the Agilent
bioanalyzer. Most RNAs were of very high quality as judged by RIN values. Pancreas RNAs had the lowest RIN values and also had the fewest
sequences that mapped to mature miRNAs
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isolated using the miRNEasy kit from Qiagen following
the manufacturer’s instructions. Dorsal Root Ganglion
RNAs were provided by Takeda Pharmaceuticals. RNAs
were quantitated using a nanodrop and, if necessary, were
concentrated by speed vac to obtain an appropriate con-
centration for library preparation prior to sequencing.
miRNA seq library construction
Library construction was performed according to Illumi-
na’s TruSeq small RNA sample prep protocol (Illumina,
San Diego CA). Library quality was assessed using the
Agilent Bioanalyzer DNA chip and quantified using Ribo
Green. Libraries were subjected to MiSeq analysis to en-
sure library quality. Body atlas libraries were assigned to
gels and lanes on the flow cells in a manner designed to
mitigate batch effect. Subsequent HiSeq analysis was
performed and 50 bp single end reads were generated
on the Illumina HiSeq 2000 platform resulting in 4–5
million reads per sample.
Data analysis by institution
Read mapping and quantification
Data was analyzed by Eli Lilly, Maastricht University and
NIEHS using separate analysis methods. The output
generated from each institution was then collated to cre-
ate a Venn diagram of the tissue enriched miRNAs iden-
tified by each analysis method. Read mapping and
quantification for the rat and dog miRNA body atlases
was performed in the following manner by Eli Lilly:
FastQ files were processed to remove adaptor sequences
and discard reads < 17 bp in length with cutadapt v.
1.4.1 [28] with options –a TGGAATTCTCGGGTGC
CAAGG–quality–base 33–q 20–match-read-wildcards –
m 17. All trimmed reads that contained an ‘N’ were dis-
carded. Identical sequences from the same sample were
combined into a single sequence in the form expected
by miRDeep2 [29]. That is, with ids of the form
“NNN_#_x#”, where NNN is a unique alphabetic code
identifying the sample, the first ‘#’ is a unique integer,
and ‘x#’ records the number of times this sequence oc-
curred in the input for the sample. Quantifier.pl from
the miRDeep2 package v. 2.0.0 was used to generate miR
alignment files (.mrd files) against known miRs from
miRbase 20 with options–P–p < org > _hairpin.fa –m<
org > _mature.fa–r trimmed_reads.fa–d. This was done
separately for rat, mouse, human, and C. elegans known
miRs. The.mrd files were then parsed with a custom Perl
script as follows. Each isomiR sequence in an alignment
was associated with the corresponding mature miR iden-
tifier. If it aligned to a miRNA precursor, but not with
an expected mature miR sequence, it was identified as <
miR > −pre to indicate this. Usually these correspond
with reverse strand miRs that have not yet been anno-
tated as alternate mature forms. Sometimes these appear
to be microRNA offset RNAs [30], and sometimes they
appear to represent incompletely processed sequence. If
a given sequence was identified as aligning with more
than one precursor, it was associated with all potential
names as a composite name. That is, a sequence that
aligned to both let-7a-5p and let-7f-5p was assigned to
the composite mature miR let-7a-5p;let-7f-5p to indicate
for subsequent analyses that this identification was am-
biguous. All sequences that had not yet been identified
against known rat miRs were then looked for in the ana-
lysis with respect to known mouse miRs, and so on
against human and finally C. elegans miRs. This process
allows for identification of conserved rodent miRs that
have not yet been annotated in rat, and against con-
served mammalian miRs that have not yet been anno-
tated in rat and mouse. In parallel to the above
identification of known miRs, we used miRDeep2’s novel
miR identification process. Additional details are de-
scribed in Additional file 1: supplementary methods.
Tissue specific and enriched miRNA identification
Data analysis of the rat and dog sequencing data was
performed by Eli Lilly as follows. Tissue specific miR-
NAs are defined as miRNAs that are expressed at a raw
count of greater than 1 in 8 out of 10 rats in 1 organ/
tissue only. For example, the brain may be the only
organ with miR-X expression, but the hypothalamus
may be the only tissue that has miR-X expressed. There-
fore, miR-X would be specific to the hypothalamus tis-
sue. Tissue enriched miRNAs are defined as miRNAs
that are expressed at a raw count of greater than 1 in 8
out of 10 rats in a few organs/tissues, typically 3–5 tis-
sues. The definition of tissue enriched was purposely
vague because a miRNA may be enriched in several or-
gans, but could still be a useful biomarker if toxicity is
only present in 1 of the organs the miRNA is enriched
in. Sex specific miRNAs are identified as miRNAs that
are expressed in 1 tissue/organ at a raw count of greater
than 1 in 4/5 males or females and in 0/5 rats in the op-
posite sex. Raw and normalized data were analyzed for
tissue specific and tissue enriched miRNAs. Animal level
data is obtained after preprocessing of the raw sequen-
cing data. For each microRNA, there are measurements
from 10 animals (5 males and 5 females) and potentially
23 different tissues. These 23 tissues were from 14 organs.
In order to find tissue specific miRNAs, tissue level counts
were obtained for each microRNA by summing over all
the animals. The tissue level counts were aggregated to
organ level by selecting the maximum of the tissue counts
to represent the organ count. For example, brain
(organ) has 4 different tissue types (Hippocampus,
Brainstem, Cerebellum, and Cerebrum), the maximum
of these 4 tissue level counts will be used to repre-
sent the expression levels of brain. After these data
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processing steps, a count data matrix is generated,
where each row corresponds to a miR and each col-
umn corresponds to an organ type.
Non-negative Matrix Factorization (NMF) [31] is a com-
monly used unsupervised learning algorithm to decom-
pose a nonnegative matrix X into 2 non-negative matrices
W and H. In our case, X is the observed count matrix of
dimension Nx14, where N is the number of miRs. Each
column of W defines a miR group and each column of H
represents the expression pattern of the miR group corre-
sponding to the organ type. Based on this decomposition,
we can find a representative set of miRs that corresponds
to the specific high expression pattern for the organ.
To identify tissue specific miRs, it has to be organ specific
(which means that it has to be highly expressed in 1 organ,
and lowly in the rest of the organs). Thus we start from
each organ specific miR, and examine if it is also highly
expressed in a particular type of tissue or a few tissues,
which belong to the current organ. For example, a miRNA
may be specific to brain (organ), but it may only be specific
to the hippocampus (tissue). To determine the expression
level of each miR, we fitted a two-component mixture of
Poisson distribution to the animal level tissue counts data.
The component with larger intensity of the Poisson distri-
bution is naturally used to model high counts and the
component with lower intensity is used to model back-
ground noise. The larger component of the Poisson mix-
ture model naturally corresponds to high expression level,
whereas the smaller component of the Poisson mixture
model naturally corresponds to the low expression level.
For an organ specific microRNA to be tissue specific, it has
to be expressed at a high level in 1 tissue of this organ.
After the mixture model is fitted and the intensities are
estimated, we can determine which tissues the microRNA
is expressed in according to their estimated intensities and
then declare tissue specific microRNAs afterwards. Add-
itionally, the raw sequencing data was manually analyzed
in each tissue for each miRNA and statistical analysis of
the manually identified tissue specific and enriched miR-
NAs was then conducted to verify or dispute the tissue
specificity or enrichment.
Read mapping and quantitation by Maastricht University
Read mapping and quantification was performed in the fol-
lowing manner by Maastricht University: mirDeep2 [32]
was used to predict putative novel miRNAs. The raw fastq
files from the 215 rat samples were mapped to the Rat gen-
ome (version 5.0.73 from Ensembl). MiRDeep2 output was
then parsed to keep only the 496 predicted miRNA precur-
sors with a score of 1 or above. Raw reads were trimmed
off the 3′ adapter sequence using the java algorithm
“Adaptor Remover” from the freely available UEA sRNA
Workbench (http://srna-workbench.cmp.uea.ac.uk/). The
parameters were set to look for a perfect match with the
first 8 bases of the 3′ adapter to be considered a hit. The
trimmed sequences with a size below 16 or above 35 bp
were discarded. During this trimming step, every identical
sequence was pulled and each iteration was summed. The
trimmed reads were then mapped to the list of rat precur-
sor miRNA obtained either from miRBase, or generated de
novo from the miRDeep2 prediction using a fast short read
mapping software PatMaN [33], configured to allow no
mismatches or gap. PatMan output was then parsed to 1)
assign a unique name to each unique sequence consisting
of the pre-miRNA name, the pre-miRNA arms (5p or 3p)
and the mapping coordinates (for instance, miR-
127_3p_57_78). 2) divide the total read count of each
unique sequence by the number of assigned loci in the
complete mapping. 3) create a mature output table by pull-
ing the different isomiR count for each miRNA species (i.e.
5p and 3p). The parsed PatMaN output were normalized
with the trimmed mean of M-values method (TMM) and
filtered to remove all miRNAs where the normalized read
counts were fewer than 10 reads in all the 215 samples.
Total read counts were then computed for each individual
miRNA.
Tissue enriched miRNA identification by Maastricht University
A miRNA was called tissue specific or tissue enriched
when the percentage of reads for a single tissue (or tis-
sue group) was respectively higher than 90 or 50 % of
the total read count.
Read mapping and quantitation by NIEHS
In order to identify isomiRs the raw count number of
each given isomiR was first converted to the percentage
of expression compared to the mature count observed
for its corresponding miRNA. By comparing this per-
centage, we were able to report the miRNA for which
the most expressed isomiRs differs between tissues.
Analysis of the data performed at NIEHS was executed
in the following manner: Raw fastq files with the miRNA-
Seq reads were checked for quality using a TQE standard
based on trimming the adapters, quality filtering at Q ≤ 20
and the elimination of short reads < 14 bases long. In
some cases when minor adapter sequences (indices) were
observed after initial process, additional rounds of pro-
cessing were applied until all the criteria were met. In the
end, reads longer than 25 base pairs were also eliminated,
resulting in quality filtered reads between 14–24 bp. Reads
passing the TQE filtering were then aligned to the rat
miRBase database v.19 using BWA version 0.6.1-r104q
with “-n 2” and default parameters otherwise. Only perfect
matches were further used in the quantification, which
was performed by summarizing read count level measure-
ments at each mature miRBase miRs. Datapoints with
zeros were imputed with 1.0. Total counts for each miR
were normalized by transcripts per million reads (TPM).
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Prior to statistical analysis, a transformation from floats to
integers was performed by ceiling the data.
Tissue enriched miRNA identification by NIEHS
To detect the tissue-enriched microRNAs, we adopted the
one-vs-rest strategy when applying statistic models. “Dif-
ferentially” expressed miRs (DEMiRs) in 1 tissue against
the combination of all other tissues were identified using a
quasi-Poisson approach (Quasi-Seq) with shrunken dis-
persion estimates [34]. During the modeling process, the
offset was computed on the 3rd quartile. Significant
DEMiRs were detected at a nominal p-value < 0.01.
Rat and dog toxicity studies
Caerulein studies: Studies were run at Covance Laborator-
ies in Greenfield, IN and histopathology was performed by
a board certified pathologist. Due to the short half-life of
caerulein [35], 6 male Sprague Dawley rats per group (ob-
tained from Charles Rivers laboratories 11–12 weeks at
study start) were treated with 3 intraperitoneal doses of ve-
hicle or caerulein (Sigma Aldrich), 1 h apart, at 0, 15 and
50 μg/kg. Blood was collected at 1, 4, 8, 24 and 48 h after
dosing and examined for clinical chemistry, hematology
and microRNA changes with terminal serum taken at 8, 24
and 48 h. Urine was collected by cystocentesis at 0, 4, 8, 24
and 48 h and examined for total protein and specific grav-
ity. Toxicokinetic analysis was performed at 0.5, 1, 4, 8, 24
and 48 h post dose. Histopathology of adrenal glands, bone
(sternum), brain stem, cerebellum, cerebrum, duodenum,
heart, ileum, jejunum, kidneys, liver, lung, muscle (plan-
taris), pancreas, spleen, stomach and thymus was examined
at 8, 24 and 48 h post dose. For canine studies, 2 beagle
dogs per group, 1 male and 1 female obtained from Cov-
ance Research Products, were given 3 doses 1 h apart of
caerulein at 3, 15 or 45 μg/kg. Blood was collected at pre-
dose, 1, 4, 8, 24, 48 and 72 h after the third dose and exam-
ined for clinical chemistry, hematology and miRNA
changes. Urine was collected by cystocentesis and exam-
ined for changes in specific gravity, BUN, creatinine and
other urinary parameters at necropsy at 24 and 72 h. Histo-
pathology on organs including adrenal glands, bone (ster-
num), brain stem, cerebellum, cerebrum, colon, epididymis,
eyes, heart, ileum, jejunum, kidneys, liver, lung, muscle
(quadriceps femoris), sciatic nerve, ovaries, pancreas, pros-
tate, spleen, stomach, testis, thymus, thyroid, uterus and va-
gina was performed at 24 and 72 h post dose. Animals
were euthanized by barbiturate overdose or anesthesia and
exsanguination at necropsy.
qPCR of serum samples from caerulein studies
For each sample, 100 μl of serum from all studies was
subjected to total RNA isolation, including miRNAs,
using the miRNeasy TM kit from Qiagen (Valencia CA).
Upon the addition of Qiazol 5 μl of 5 μM synthetic cel-
miR-55-3p (IDT) was spiked into each sample in the rat
caerulein and dog caerulein studies. RNAs were eluted
in 80ul of 95 °C H2O and a water extraction control
with spike-in was also included. Reverse transcription
was executed with the miRCURY LNA microRNA Uni-
versal cDNA Synthesis Kit (Copenhagen, Denmark).
10 μl of the extracted RNAs were used in 20 μl RT reac-
tions. A no template control (NTC) and two -RT con-
trols were also included. Real-Time PCR was conducted
using Exiqon (Additional file 2) primers and ExiLENT
SYBR Green Master Mix (Copenhagen, Denmark). Sam-
ples were diluted 1:40 prior to qPCR and 5 μl of the di-
luted samples were used in 10 μl reactions. Data was
collected on a 7900HT Real-Time PCR instrument (Life
Technologies, Grand Island, NY).
Statistical analysis of rat and dog caerulein qPCR data
For each study, the fold change data were log2 trans-
formed and fitted to a two-way ANOVA model with
repeated measures. Because each animal has multiple
measurements, we allow these measurements to be
auto-correlated. Once we obtained the parameter esti-
mates, for the dog study, all treatment means and
95 % confidence intervals at each time point are com-
pared against the pre-dose group, which have FC
fixed at 1. For the rat study, low dose and high dose
groups are compared to untreated group at each time
point.
qPCR validation of tissue specific and enriched miRNA
Tissue enriched and tissue specific miRNAs were chosen
for qPCR validation. The RNAs from 3 rats and 21 tissues
were normalized by mass (1 ng of RNA per tissue) and
subjected to cDNA synthesis using Exiqon universal
cDNA synthesis kits (Cat# 203301) and ExiLENT SYBR
green mastermix (Cat# 203421). Data was collected on a
7900HT or ViiA7 Real-Time PCR instrument (Life
Technologies, Grand Island, NY). Assays were designed to
the most highly expressed miRNA or isomiR sequence
present that mapped to the mature miRNA. For example,
many isomiRs mapped to miR-XYZ. For qPCR analysis we
designed primers to the most highly expressed miRNA se-
quence that mapped to miR-XYZ as determined by deep
sequencing. Ct values of each miRNA were compared to
one another to determine tissue specificity or enrichment.
A Ct value was considered acceptable if the Ct in a par-
ticular tissue was 10 Cts lower than the signal in the no
RT or no template (NTC) controls unless there was no
signal in the no RT or NTC. If an assay did not display a
signal that was not 10 Cts away from the no RT or NTC it
was not included in the analysis. Additionally, if the melt
curves for an assay displayed more than one peak the
assay was not included in the analysis.
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qPCR analysis of pancreas enriched miRNAs
Total RNA from all male and female rats used in the
study were normalized by mass using 250 ng of RNA
per sample and subjected to cDNA synthesis using Exi-
qon universal cDNA synthesis kits (Cat# 203301) and
ExiLENT SYBR green mastermix (Cat# 203421). Data
was collected on a 7900HT or ViiA7 Real-Time PCR in-
strument (Life Technologies, Grand Island, NY).
Results
Our first objective was to identify miRNAs expressed in
rat tissues. Members of the HESI consortium were quer-
ied on which rat organs are most commonly injured dur-
ing toxicology studies and therefore, would represent the
most important organs to investigate for potential bio-
markers of injury. This resulted in the list of organs de-
tailed in Fig. 1. Dorsal root ganglion was added as an
organ of investigative interest. The brain lacks serum
and cerebrospinal fluid (CSF) based biomarkers of in-
jury, therefore the miRNA content of the cerebrum,
cerebellum, hippocampus and brainstem were interro-
gated. Additionally, whole blood was included in the
study in order to determine what the contribution of
blood miRNAs may be to highly vascularized tissues.
Total RNA was isolated from the tissues of male and fe-
male SD rats and the quality was assessed using RIN
values (Fig. 1) to be sure that small RNAs would be se-
quenced as opposed to degraded RNAs. The rat micro-
RNA sequencing data, as analyzed by Eli Lilly, generated
1,927 sequences that mapped to previously-identified
mature microRNAs in rat, mouse and human. This re-
sulted in an increase of 1,162 miRNAs in the rat as com-
pared to the 765 mature rat miRNAs in miRBase v21.
While Eli Lilly’s data analysis serves as the main source
of data for discussion in this article we also collaborated
with HESI members to analyze the data in an attempt to
maximize our ability to discover and confirm the tissue
enrichment profile of miRNAs (Fig. 2).
Our second objective was to discover novel and con-
firm previously identified tissue specific and/or tissue
enriched miRNAs and/or isomiRs that could be used as
serum based biomarkers of organ injury in the rat. A
variety of data analysis software packages and statistical
methods exist to identify and predict miRNAs and per-
form differential expression on miRNA-seq data [36, 37].
Since these methods have different strengths and weak-
nesses and the most suitable data analysis method is
dependent on the output required, different methods
were employed by scientists at Eli Lilly, NIEHS and
Maastricht University to analyze the sequencing data in
order to maximize discovery of tissue enriched miRNAs.
The tissue enriched miRNAs identified by each institu-
tion were included in a Venn Diagram in order to deter-
mine which tissue enriched miRNAs were found in
common between each data analysis method (Fig. 3).
Tissue specific miRNAs identified by Lilly are reported
in Table 1 and were not included in the Venn diagram.
Maastricht University identified 355 tissue enriched
miRNAs, Eli Lilly identified 481 tissue enriched miRNAs
and NIEHS identified 660 tissue enriched miRNAs.
Fig. 2 Workflow diagram. The small RNA content of rat organs was
interrogated by deep sequencing and the data was given to 3
institutions for independent data analysis. Reads were mapped to
rat, mouse and human miRNAs from miRBase v19 and v20 using
miRDeep2 and tissue specific and tissue enriched miRNAs
were identified
Fig. 3 Venn diagram of data analysis methods. Analysis of the
miRNA sequencing data was independently performed by Eli Lilly,
Maastricht University and the NIEHS using different data analysis
methods. Eli Lilly identified 481 tissue enriched miRNAs, Maastricht
University identified 355 tissue enriched miRNAs and the NIEHS
identified 660 tissue enriched miRNAs. The number of miRNAs in
common between Maastricht University and Eli Lilly was 167, the
number of miRNAs in common between Maastricht University and
the NIEHS was 202 and the number of miRNAs in common between
Eli Lilly and the NIEHS was 401. The number of miRNAs in common
between all 3 analysis was 165
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Maastricht University and Eli Lilly had 167 miRNAs in
common, Maastricht University and NIEHS had 202
miRNAs in common, Eli Lilly and NIEHS had 401 miR-
NAs in common and all 3 institutions had 165 tissue
enriched miRNAs in common (Additional file 3: Table
S1). Differences in the results from each institution are
due to the processing steps prior to alignment, the refer-
ence sequences the sequencing data were aligned to and
the methods of identifying tissue specific and/or enriched
miRNAs. Despite which approach was taken each analysis
identified many of the same tissue enriched miRNAs and
the data has been made publically available for researchers
in industry, academia or government to explore and po-
tentially discover additional tissue specific and/or enriched
miRNAs which may serve as novel biomarkers for safety,
pharmacodynamic or other effects.
Tissue specific and enriched miRNAs identified by
Lilly are shown in (Additional file 4: Table S2) and
(Additional file 5: Figure S1) and the tissue enriched
miRNAs identified by NIEHS and Maastricht University
are shown in (Additional file 6: Table S3 and Additional
file 7: Table S4 respectively). The tissue specificity/en-
richment of many other tissue enriched miRNAs includ-
ing muscle and heart enriched miRs-133a-3p, 499-5p,
miR-1a-3p as well as pancreas enriched miRs-216a-5p,
217-5p and miR-375-3p were confirmed [38–40] (Fig. 4).
The brain, testis and liver have the most tissue specific
and enriched miRNAs and interestingly, tissue enriched
miRNAs in the brain are often expressed in the intestine.
The kidney has the fewest tissue specific and enriched
miRNAs of any organ examined, while skeletal muscle
and heart share several of the same tissue enriched miR-
NAs. While previously identified tissue specific and
enriched miRNAs were verified, previously unidentified
tissue specific/enriched miRNAs were discovered in-
cluding, but not limited to, pancreas enriched miRs-
148a-3p, 141-3p and 200c-3p (Additional file 4: Table
S2). In order to verify that miRNAs were, in fact, tissue
specific or enriched we conducted qPCR verification of
some of the tissue specific and/or enriched miRNAs
(Additional file 8: Table S5). As shown in Fig. 5, 27 of
the 39 miRNAs tested correlated very well to the se-
quencing data with a correlation of − 0.8 to − 1.0, 8
miRNAs displayed a correlation of − 0.79 to − 0.57 and
4 miRNAs displayed poorer correlations from − 0.33 to
− 0.22 (Fig. 5 and Additional file 9: Table S6). MiRs-
196c-5p and 206-5p were not amplified by qPCR and,
therefore, did not display tissue specificity or enrich-
ment by qPCR.
While each institution was able to identify tissue spe-
cific and enriched miRNAs it is also imperative to
understand whether the isomiRs of the tissue specific
and enriched miRNAs are expressed in the same tissues
as the parent miRNA as isomiR expression in other tis-
sues could lead to inaccurate interpretation of serum
miRNA profiles with respect to toxicity. Eli Lilly investi-
gated the isomiR expression of pancreas tissue specific
and enriched miRNAs and the analysis revealed that iso-
miRs generally mirror their parent miRNA expression
(Additional file 10: Figure S2), but some isomiRs are
more tissue specific than others as shown for miR-215
in the intestines (Additional file 11: Figure S3) and miR-
217-5p in the pancreas (Additional file 10: Figure S2).
For example, the mature miR-217-5p sequence is 5′
TACTGCATCAGGAACTGACTGG-3′ and the isomiR-
217-5p sequence 5′-TACTGCATCAGGAACTGACTG-
GAC-3′ are both highly enriched in the pancreas, but
the miR-217-5p isomiR lacks expression in the stom-
ach, intestine and ovary while other isomiRs of miR-
217-5p are expressed in the stomach, intestine and
ovary (see the last miR-217-5p isomiR in Additional file
10: Figure S2). IsomiRs in other tissues such as isomiRs
of miR-215 in the intestine (Additional file 11: Figure
S3), miR-192-5p in the liver (Additional file 12: Figure
S4) and miR-3473f-pre in the testis (Additional file 13:
Figure S5 and Additional file 14: Figure S6) display
similar isomiR expression. It appears that interpretation
of serum miRNA toxicity biomarker data should not be
compromised by expression of isomiRs from tissues
lacking parent miRNA expression.
Table 1 Rat tissue specific miRNAs
Tissue miRNA
Adrenal miR-126b, miR-494-5p, mir-134-pre, miR-3544, miR-299a-
5p;miR-299b-5p
Brainstem miR-296-3p, miR-7047-3p, miR-186-3p
Cerebellum mir-1928-pre, mir-484-pre, miR-130a-3p;miR-130b-3p,
miR-6125, miR-154-3p
Cerebrum miR-218-5p, miR-466i-5p;mir-466 k-pre;mir-466q-pre,
miR-410-5p, miR-344 g, mir-504-pre, miR-344b-1-3p;miR-
344b-2-3p, miR-551b-5p, miR-103-2-5p
Heart miR-208a-3p, miR-208a-5p, miR-126-3p, miR-6314, miR-
509-3p
Ileum miR-2137, miR-3195, miR-320-5p, miR-4448
Liver miR-101b-5p, miR-122-3p, miR-1195, miR-466c-3p, miR-
293-5p, miR-466b-2-3p;miR-466c-3p;mir-466d-pre, miR-
692, miR-466b-2-3p, mir-328-pre, miR-466f-3p, mir-5131-pre
Medulla miR-200b-3p;miR-429
Muscle Biceps miR-675-5p
Muscle Soleus miR-206-5p, miR-1273 g-3p;mir-1273a-pre
Pancreas miR-320c, miR-148b-3p;miR-152-3p
Whole Blood mir-466q-pre, miR-7687-5p, miR-3656;mir-3195-pre, miR-
3473b;mir-3473d-pre, miR-6937-5p
Tissue specific miRNAs were defined as miRNAs there are expressed at a raw
count of >1 in 8/10 rats in 1 tissue only. Sequencing data was analyzed by
non-negative matrix factorization which identified tissue specific miRNAs.
Organs not listed in the table did not have tissue specific miRNAs
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Rat and dog Pancreas toxicity studies
Conserved pancreas tissue enriched miRNAs were exam-
ined in the rat and dog models of caerulein pancreatic
toxicity in order to begin to characterize miRNAs as spe-
cies translatable serum based biomarkers of pancreatic in-
jury (Table 2). Rats were treated with vehicle, 15 and
50 μg/kg of caerulein and the serum was examined for
clinical chemistry and miRNA changes at 1, 4, 8, 24 and
48 h with histopathologic assessment of organs at 8, 24
and 48 h. Minimal and slight pancreatic necrosis was
noted in 4 vehicle treated rats at 24 and 48 h which had
no clinical chemistry or miRNA correlates and were con-
sidered to be consistent with common background while
minimal, slight, moderate and marked pancreatic necrosis
was noted in the 15 and 50 μg/kg treated rats that was
interpreted to be dose related (Fig. 6). Clinical chemistry
parameters including amylase and lipase (markers of pan-
creas injury), miR-122-5p (liver enriched), miR-133a-3p
(muscle enriched), 148a-3p (pancreas enriched), 208a-3p
(heart enriched) and pancreas miRNAs conserved be-
tween rat and dog (Table 2) were examined for changes in
the serum. MiR-216a-5p, amylase and lipase were in-
creased in the serum concurrently at 1 h, remained ele-
vated until 8 h while miR-216a-5p remained elevated until
24 h. MiR-217-5p displayed similar kinetics to miR-216a-
5p except miR-217-5p generally had a larger dynamic
range and remained elevated until 48 h. Both miRs-216a-
5p and 217-5p displayed much larger dynamic ranges than
amylase or lipase and remained elevated longer. MiR-





























































































Fig. 4 Heat map of tissue specific and tissue enriched miRNAs. Examples of tissue specific and enriched miRNAs identified by this and previously
published studies are displayed with tissues on the x-axis and miRNAs listed on the y-axis. MiRNA expression from least to highest expression is
indicated as a shift from blue to red with blue representing the least expression and dark red indicating maximal expression
Smith et al. BMC Genomics  (2016) 17:694 Page 10 of 19
similar to amylase and lipase, but had a dynamic range
that was less than lipase and greater than amylase. MiR-
375-3p was increased from 4–24 h in the 15 and 50 μg/kg
groups and returned to approximately vehicle level by
48 h. The pancreas enriched miRNAs conserved between
rat and dog (miR-101c, 141-3p, 148a-3p, 193b-3p, 200c-
3p,) that were tested displayed increases in the serum
similar to amylase (data not shown), whereas miRs 320-
3p, 4286 and 5100 were not increased (Fig. 7 and statis-
tical analysis Additional file 15: Table S7).
Marshall beagle dogs were treated with vehicle, 3, 15
and 45 μg/kg of caerulein and the serum was examined
for clinical chemistry and miRNA changes at 1, 4, 8, 24,
48 and 72 h with histopathologic assessment of organs
at 24 and 72 h. Pancreatic necrosis was noted in 1 dog
at 24 h in the 15 μg/kg group and 24 and 72 h in the
45 μg/kg group (Fig. 8). Amylase and lipase were not in-
creased greater than two fold in the vehicle or 3 μg/kg
treated dogs at any time point. Amylase and lipase were
increased in the 15 μg/kg treated dogs with the largest
increases at 1 h and decreasing by 8–24 h while both
were increased maximally at 4-8 h in the 45 μg/kg
treated group. MiR-216b-5p was increased in 1 vehicle
treated animal and miR-217-5p was increased in 2 ve-
hicle treated animals with no histopathologic or clinical
chemistry correlates (data not shown). In 3 μg/kg treated
dogs miR-216b-5p and miR-141-3p were increased at
some time points, but miR-216b-5p was not increased
beyond the level of the vehicle treated dog and did not
display consistent time dependent increases. MiR-141-3p
and miR-216a-5p were increased beyond vehicle treated
dogs and did not display consistent time dependent in-
creases. MiR-375-3p did display increases as compared
to vehicle reaching its maximum increase at 1 h and
remaining elevated until 24 h. In 15 μg/kg treated dogs
Fig. 5 Correlation of qPCR analysis of tissue specific and/or enriched
miRNAs. Tissue specific and/or enriched miRNAs were chosen
according to tissues that lack or require additional biomarkers of organ
status and were measured in 21 tissues from 3 female rats by qPCR.
The qPCR data was compared to the sequencing raw counts for each
miRNA. A perfect correlation is equal to− 1 because the Ct value
decreases as sequencing abundance increases. Twenty seven of the
thirty nine miRNAs tested correlated very well to the sequencing data
with a correlation of− 0.8 to− 1.0, 8 miRNAs displayed a correlation of
− 0.79 to− 0.57 and 4 miRNAs displayed poorer correlations from−
0.33 to− 0.22. MiRs-196c-5p and 206-5p were not amplified by qPCR
and, therefore, did not display tissue specificity or enrichment by qPCR
Table 2 Pancreas enriched miRNAs conserved between rat and dog
Rat pancreas Sequence (5′-3′) Dog Pancreas Sequence (5′-3′)
miR-101c TACAGTACTGTGATAACTGATC miR-101c ACAGTACTGTGATAACTGACC
miR-141-3p TAACACTGTCTGGTAAAGATG miR-141 TAACACTGTCTGGTAAAGATG
miR-193b-3p AACTGGCCCACAAAGTCCCGCT miR-193a-3p AACTGGCCTACAAAGTCCCAGTT
miR-200c-3p TAATACTGCCGGGTAATGATGGA miR-200c TAATACTGCCGGGTAATGATGGA
miR-216a-5p TAATCTCAGCTGGCAACTGTG miR-216a TAATCTCAGCTGGCAACTGTGA
miR-216b-5p AAATCTCTGCAGGCAAATGTGA miR-216b AAATCTCTGCAGGCAAATGTGA
miR-320-3p AAAAGCTGGGTTGAGAGGGCGA miR-320b;miR-320c AAAAGCTGGGTTGAGAGGGAA
miR-4286 ACCCCACTCCTGGTACCA miR-4286 ACCCCACTCCTGGTACCA
miR-5100 ATCCCAGCGGTGCCTCCA miR-5100 GTTCGAATCCCAGCGGTG
miR-217-5p TACTGCATCAGGAACTGACTGGA miR-217 ATACTGCATCAGGAACTGATT
miR-375 TTTGTTCGTTCGGCTCGCGTGA miR-375 TTTGTTCGTTCGGCTCGCGTGA
Tissue enriched miRNAs conserved between rat and dog were identified and are shown above. These miRNAs were analyzed for changes in the serum in
rat and dog caerulein toxicology studies. Bases underlined indicate bases that are not conserved between the rat and dog isomiRs with the highest
sequencing counts
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miRs-216a-5p, 216b-5p, miR-375-3p and 141-3p were
increased in a time dependent manner with maximal in-
creases at 4–8 h (Fig. 9 and statistical analysis Additional
file 16: Table S8). MiR-216a-5p displayed the greatest dy-
namic range reaching as high as 103 fold above vehicle.
In the 45 μg/kg treated dogs amylase, lipase and miR-
NAs displayed dose and time dependent increases. MiR-
216a-5p was increased maximally at 4–8 h and remained
elevated until 72 h while levels as high as 5,494 fold
above vehicle were observed in individual animals. MiR-
216b-5p reached levels as high as 649 fold above vehicle
in individual animals and remained elevated until 24 h.
The remaining miRNAs did increase and remained ele-
vated generally as long, but not to the degree of miRs-
216a-5p and 216b-5p. Interestingly, liver enriched miR-
122-5p was increased in a dose and time dependent
manner while AST and ALT were increased in the 45 μg/
kg treated dogs while no histopatholgic correlate was ob-
served (data not shown). The rat caerulein study did not
generate similar miR-122 increases. As demonstrated by
these studies, miRNAs can serve as species translatable
serum based biomarkers of pancreatic injury.
Discussion
We have generated a rat miRNA body atlas and identi-
fied an additional ~1200 potential miRNAs in the rat as
compared to the current number of rat miRNAs in miR-
Base v21. We have also confirmed many previously iden-
tified tissue specific and enriched miRNAs and have
discovered many previously unknown rat tissue specific
and enriched miRNAs. Rat and dog miRNA atlases were
compared in order to determine which miRNAs are
conserved and may represent species translatable bio-
markers of organ injury. Subsequently, the conserved
pancreas enriched miRNAs in rats and dogs were dem-
onstrated in pancreas toxicology studies to be sensitive
blood-based biomarkers of caerulein induced pancreatic
injury in both species.
The aims of this study were 3 fold. First we sought to
comprehensively catalogue the miRNA and isomiR con-
tent of the major organs of toxicologic interest in the rat
in order to discover potential miRNA biomarkers of
organ injury. Secondly, we wanted to identify tissue spe-
cific and tissue enriched miRNAs that may serve as bio-
markers of organ injury. Thirdly, we wanted to test
tissue specific and/or enriched miRNAs that are con-
served in the rat and dog in toxicology studies to deter-
mine whether conserved miRNAs could be used as
serum based biomarkers of organ injury in both species.
While others have generated similar data using micro-
array or qPCR, next generation sequencing is advanta-
geous in that it allows for the discovery of miRNA
Fig. 6 Histopathologic assessment of the pancreases of rats treated with 15 and 50ug/kg of caerulein. Histopathologic assessment of organs was
performed at 8, 24 and 48 h with dose, time and animal number indicated on the x-axis and the grade of injury indicated on the y-axis (grey-blue
indicates slight injury, green indicates moderate injury, blue indicates minimal injury and pink indicates marked injury). Rat pancreases displayed
minimal and slight pancreatic necrosis in 4 vehicle treated rats at 24 and 48 h while dose responsive increases in the severity of necrosis was
noted in the 15 and 50ug/kg treatred rats at 8, 24 and 48 h
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sequences without the need for prior genome annotation
[41]. Analysis of the sequencing data refined the tissue
specific/enrichment of previously reported tissue specific
miRNAs and revealed many previously undiscovered tis-
sue specific and enriched miRNAs.
Identification of tissue specific and enriched miRs and
isomiRs
Independent data analysis, utilizing different techniques,
was performed by members of HESI. Approximately 165
tissue enriched miRNAs were found to be in common
between the data analysis methods and additional tissue
enriched miRNAs were identified by each institution. In
order to ensure that interpretation of serum miRNA
profiles is reflective of organ specific toxicity we sought
to determine the tissue specificity and enrichment of the
isomiRs of tissue specific and enriched miRNAs identi-
fied by Eli Lilly. Eli Lilly identified many sequences that
mapped to mature miRNAs which consisted of se-
quences that differed from the mature miRNA sequence.
These sequences, termed isomiRs [26] contained add-
itional bases on the 5′ and 3′ ends as compared to the
reference miRNA sequences and were also evaluated for
tissue specificity and enrichment. We determined that
the isomiRs of tissue specific and enriched miRNAs,
with some exceptions, did generally mirror the expres-
sion of the reference miRNA sequence indicating that
serum miRNA profiles should accurately reflect organ
toxicity. Some isomiRs did display increased tissue speci-
ficity/enrichment as compared to the parent miRNA and
these could serve as more specific markers of organ in-
jury when faced with multiple organ toxicity.
Eli Lilly’s definition of a tissue enriched miRNA was
purposefully vague because some miRNAs may be
expressed in multiple organs at a higher level than the
remaining organs, but may still be reasonable candidate
biomarkers of organ injury depending on the observed
toxicity. It is possible that a miRNA that is enriched in
several tissues could be a useful marker of tissue injury
if toxicity is restricted to a single organ that the miRNA
is expressed in. In the face of multiple organ toxicity this
approach may not be reasonable unless additional bio-
markers could improve interpretation of the injury.
Consequently, some miRNAs may not appear to be par-
ticularly tissue enriched as shown in Additional file 5:
Figure S1.
Fig. 7 Clinical chemistry and serum miRNA analysis of caerulein treated rats. Rats treated with 0, 15 and 50ug/kg of caerulein were examined for
clinical chemistry and miRNA changes (doses are indicated by red, green and blue respectively). Time is indicated on the x-axis and the log 2 of
the fold change, the mean as well as 95 % confidence interval are indicated on the y-axis. miRNAs were incereased in the serum of rats with 15
and 50 ug/kg of caerulein coincident with increases in amylase and lipase with maximal increases occurring at 8–24 h for miRs-216a-5p, 217-5p
and 375-3p. Values are normalized to vehicle and to the cel-miR-55-3p spike in
Smith et al. BMC Genomics  (2016) 17:694 Page 13 of 19
Rat and dog Pancreas Toxicity Studies
In order to characterize pancreas enriched miRNAs con-
served between rat and dog as potential biomarkers of
pancreatic injury we conducted rat and dog caerulein
studies in which animals were treated with caerulein and
concurrent clinical chemistry and histopathology were
assessed along with miRNA changes in time course
studies. Amylase and lipase increases were noted from
1–8 h in rats in both 15 and 50 μg/kg dose groups while
pancreatic necrosis was noted at 8, 24 and 48 h. MiR-
375-3p has been reported to be enriched in islets and
the miRNA with the highest intra-islet expression [38]
and in our study was increased from 4–24 h in the 15
and 50 μg/kg groups, returning to approximately vehicle
level by 48 h. MiR-216a-5p and miR-217-5p remained
elevated in the serum of rats longer than amylase or lip-
ase and had a much greater dynamic range which could
be advantageous if detection of pancreatic injury is not
able to be examined at earlier time points.
Dogs treated with caerulein displayed serum amylase
and lipase increases in the 15 μg/kg group from 1–8 h
while showing increases in the 50 μg/kg group from 1–
24 h. MiR-216a-5p levels increased prior to amylase and
lipase and correlated well to amylase and lipase in the
15 and 50 μg/kg groups, but remained elevated longer
and to a much larger degree than amylase and lipase.
MiR-216b displayed similar kinetics to miR-216a-5p, but
with a reduced dynamic range while miR-217-5p dis-
played increases similar to amylase. Interestingly, miR-
217-5p displayed very large increases for the longest
amount of time in the rat and this result was not
reflected in the dog. This difference could reflect species
differences in the toxicity of the compound, differences
in the relative amount of the miRNA in dog pancreas or
Fig. 8 Histopathologic assessment of the pancreases of dogs treated with caerulein. Marshall beagle dogs were treated with 3, 15 and 45 ug/kg
of caerulein and histopathologic assessment of organs was performed at 24 and 72 h with dose, time and animal number indicated on the x-axis
and the grade of injury indicated on the y-axis (pink indicates minimal injury and green indicates moderate injury). Pancreatic degeneration/
necrosis was not noted in dogs treated with 3ug/kg of caerulein. Pancreatic degeneration/necrosis was noted in 1 dog at 24 h in the 15ug/kg
group and displayed dose dependent increases in severity at 24 and 72 h in the 45ug/kg group
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differences in the stability or clearance of the miRNA in
dog serum. MiRs-141-3p and 200c-3p appeared to in-
crease prior to amylase or lipase in the 3 μg/kg group
and displayed increases similar to amylase in the 15 and
45 μg/kg groups while miR-148a-3p displayed increases
similar to amylase. MiR-375-3p was increased prior to
amylase and lipase at 3 μg/kg, correlated well with amyl-
ase and lipase in the 15 and 45 μg/kg dose groups and
had a much larger dynamic range in the dog study as
compared to the rat study. The other conserved pan-
creas enriched microRNAs tested were not correlated to
clinical chemistry or histopathologic changes. These ob-
servations are important and demonstrate that miRNAs
may display different kinetics in different species. There-
fore, different miRNAs may have more favorable charac-
teristics as biomarkers in different species and should be
thoroughly investigated in each.
Interestingly, liver enriched miR-122-5p was increased
in a dose and time dependent manner while AST and
ALT were increased in the 45ug/kg treated dogs with no
observed histopatholgic correlate. The rat caerulein
study did not generate similar miR-122 increases. It is
possible that, due to species differences in injury and
physical proximity, pancreatic damage induced by caeru-
lein in dogs caused some perturbation of the membranes
of hepatocytes resulting in AST, ALT and miR-122-5p
increases in the serum while not producing similar re-
sults in the rat. Additionally, individual rats and dogs
displayed large differences in the amount of miRNA in-
creased in the serum. This may be due to individual ani-
mal variation in the pancreatic damage, differing stability
of the miRNAs or lack of miRNA normalization similar
to tubulin or GAPDH used for mRNA comparisons as
all samples were normalized by serum volume.
We tested several conserved pancreas enriched miR-
NAs in rat and dog pancreas toxicity studies and deter-
mined that the miRNAs perform as well or better than
traditional markers of pancreas injury. Based on these
studies miR-216a-5p displayed the largest dynamic range
and correlated well with amylase and lipase indicating
Fig. 9 Clinical chemistry and serum miRNA analysis of caerulein treated dogs. Dogs treated with 3, 15 and 45 ug/kg of caerulein were examined
for clinical chemistry and serum miRNA changes (doses are indicated by red, green and blue respectively). Time is indicated on the x-axis and the
log 2 of the fold change, the mean as well as 95 % confidence interval are indicated on the y-axis.. miRNAs were increased in the serum of dogs
trreated with 3ug/kg of caerulein prior to increases in amylase and lipase. miRNAs were dose dependently increased in the serum of dogs treated
with 15 and 45 ug/kg of caerulein and correlated to amylase and lipase increases while miR-216a-5p remained elevated until 24 h. Values are
normalized to vehicle and to the cel-miR-55-3p spike in
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that it is the best translatable miRNA biomarker that
correlated to pancreatic injury from rat to dog. It is pos-
sible that additional pancreas specific and/or enriched
miRNAs may supplement the interpretation of pancre-
atic injury or serve as better biomarkers than miR-216a-
5p in pancreatic toxicity studies utilizing different
pancreatic toxicants. The data generated in this study
verified our rationale for generating a library of rat tis-
sue/organ specific and enriched miRNAs. These data
can serve as a resource for future research by the scien-
tific community for discovery and characterization of
additional miRNA biomarkers as well as a resource for
more comprehensive isomiR analysis.
Additional considerations
While the work here has advanced the knowledge of the
miRNA and isomiR content of rat organs it is important
to note that the quantitative capacity of miRNA sequen-
cing may be inaccurate due to ligase bias as certain miR-
NAs may be under or over-represented and potentially
not detected [42–44]. The sequencing data and subse-
quent analysis did identify many tissue enriched miR-
NAs previously discovered through other methods,
therefore it is reasonable to infer that ligase bias may
not be dependent on the RNA content of a particular
sample, but may be dependent on the base composition
of an individual miRNA. Ligase bias most certainly af-
fected the quantitative capacity of miRNA sequencing in
this study (Additional file 17: Figure S7 and Additional
file 18: Figure S8) as the quantitation of miRs-216a-5p,
375-3p and 148a-3p did differ between the sequencing
data and qPCR. It is also possible that ligase bias could
affect quantitation of isomiRs and this could affect
which miRNA sequences are targeted for detection in
the serum by qPCR or other technologies. QPCR assays
in the caerulein studies conducted here were chosen
based upon the sequences that aligned to the mature
miRNA with the highest expression level. This may have
resulted in picking an isomiR sequence that was
expressed at a different level than the sequencing data
indicated. If a miRNA is not expressed at a high level in
a tissue then it would be reasonable to conclude that lit-
tle would be detectable in the serum and this could be
an additional reason why some miRNAs did not appear
to perform as well as others in the toxicology studies
conducted here. In addition, as methods for improving
ligase bias improve, reanalysis of the miRNA content of
rat organs may need to be performed or analytical
models may be developed that could account for ligase
bias to gain a true understanding of miRNA quantity in
each organ and potentially detect additional miRNAs.
IsomiRs generally displayed more variation on the 3′
ends which can affect the selection of the most appro-
priate qPCR assay to use for detection, therefore
selection of the sequence present in the greatest
amount should result in optimal detection of injury if
the miRNA is released upon cellular injury, stable in
the blood, present in sufficient amount and ligase bias
is not a confounding factor. Improvements in the quan-
titative capacity of miRNA sequencing could also result
in changing which miRNA is defined as the mature
miRNA sequence in miRBase and other miRNA cata-
loguing databases.
An advantage of miRNAs as biomarkers of organ in-
jury is the potential for species translatability of the
biomarker for organ toxicity using the same assay to
detect the miRNA. It is possible that expression of
miRs and isomiRs could change in the tissues of com-
pound treated animals. Therefore, it would be worth-
while to determine if the tissue specificity/enrichment
and expression levels of miRNA sequences change in
response to toxic insult. Ultimately, toxicology studies
examining the kinetics of tissue specific and enriched
miRNAs utilizing a variety of compounds eliciting tox-
icity in a particular organ in different species will likely
be needed to establish which microRNAs are the best
species translatable serum based biomarkers of organ
injury. Studies may also need to be conducted with a
wide variety of toxicants to determine which miRNAs
are subject to the least amount of change in expression
level in serum in order to determine if a serum miRNA
could be used for normalization. Additionally, deter-
mining reference ranges for miRNAs of interest will be
a topic that will need to be investigated with additional
toxicology studies in the future. This could assist re-
searchers in determining what degree of change corre-
lates to what degree of organ injury. Clearly, miRNAs
will need to be rigorously evaluated in a manner simi-
lar to other biomarkers [45, 46]. While the major or-
gans of toxicologic interest were examined, not all
tissues in the rat or dog were examined. Therefore, tis-
sues such as the thyroid, parathyroid, lung, spleen, fat,
bone, cartilage, skin, spinal cord, peripheral neurons and
other tissues could also be examined in future studies for
their miRNA content. Moreover, as shown in this study,
different data analysis methods can generate different
numbers of tissue enriched miRNAs. These data may yield
additional candidate biomarkers of organ injury if different
data analysis methods are employed.
As further characterization of serum miRNA bio-
markers is conducted, a qPCR based panel or a method
utilizing multiplexing of miRNAs representative of each
organ with multiple miRNAs per organ may be gener-
ated and used regularly in toxicology studies utilizing
biomarkers as the major or a complimentary method for
determining organ toxicity. This method could ultim-
ately detect toxicity in organs with validated miRNA bio-
markers using a small volume of serum and may
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significantly reduce the cost of preclinical and clinical
drug development.
Conclusions
Using a next generation sequencing approach, we have
generated a rat miRNA body atlas. In that process
we discovered an additional 1,162 potential rat miR-
NAs, verified previously identified tissue specific and
enriched miRNAs, identified many new tissue specific
and enriched miRNAs, and analyzed isomiR expres-
sion of tissue specific and enriched miRNAs. In
addition, we provided proof of concept that pancreas
enriched miRNAs conserved between rat and dog
could be used as serum based markers of pancreatic
injury in rat and dog caerulein toxicology studies. In
collaboration with Takeda and HESI we have analyzed
the dog miRNA sequencing data and determined
which tissue specific and enriched miRNAs were con-
served between the 2 species. Finally, we determined
that miR-216a-5p appears to perform as well or better
as a marker of pancreatic injury than amylase, lipase
or other pancreas enriched miRNAs in rat and dog
caerulein toxicity studies.
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